From the 2012 AACR Meeting – Systemic Inflammation and Survival in Men with Prostate Cancer: Evidence from the Glasgow Inflammation Outcome Study.
I met with Dr. Kashif Shafique of the University of Glasgow who was the senior author of a research poster presented at the meeting. He and his colleagues look at the relationship between systemic inflammation [...]
Announcing Early Access To Alpharadin (Radium-233 Chloride)
I am interrupting the reviews of the AACR meeting to inform you of a very important piece of news. Men with advanced prostate cancer which is castrate resistant and who have 2 blaistic bone metastases [...]
A Video Interview About My Experience at the AACR Meeting in Chicago
Patient Power, a Partner Organization of Malecare, just released a Skype interview they made with me about some aspects of the recent AACR meeting in Chicago. I talk about the exciting results from the Phase [...]
More from the 2012 AACR Meeting – The Impact of Curcumin plus Docetaxil in Castrate Resistant Prostate Cancer
Curcumin is thought to have anti-cancer activity as well as to provide a synergistic effect with chemotherapy agents. Because of this Dr. Eloise Planchat of the Centre Jean Perrin, Division de Recherche Clinique, EA4231, Université [...]
From The AACR 2012 Meeting – Does Lycopene Effect Prostate Cancer?
From The AACR 2012 Meeting - Does Lycopene Effect Prostate Cancer? Yesterday’s post was about the themes I saw in cancer research. Starting today I will be reporting specific research items I saw at the [...]
Some Important Themes From The 2012 AACR Meeting
Last week I had the privilege of attending the Annual 2012 American Association of Cancer Researchers (AACR) in Chicago through the generosity of the Scientist-Survivor Program. The meeting involved five days of educational sessions, symposia [...]